STABLE ATORVASTATIN COMPOSITIONS OBTAINED BY HUMID GRANULATION Russian patent published in 2008 - IPC A61K31/40 A61K9/14 A61K9/16 A61P3/06 A61K9/20 

Abstract RU 2332211 C2

FIELD: medicine.

SUBSTANCE: invention describes pharmaceutical atorvastatin composition granulated by humid method with at least ca. 5% (mass) addition of alkali-earth metal salt containing: (a) atorvastatin, where atorvastatin is at least partly disordered form or mix of crystal and disordered atorvastatin forms, or its pharmaceutically acceptable salt; and (b) fluffer or combination of fluffers selected out of a group including sodium starch glycolate, starch, corn starch, preliminarily gelatinised starch, sodium alginate, cellulose powder, hydroxypropyl cellulose, magnesium aluminosilicate and potassium polacrylin, where the claimed atorvastatin composition granulated by humid method contains not more than ca. 3% of atorvastatin lactone, on the basis of ratio of lactone peak to the combined peak areas of total formulation, defined by high-efficiency liquid chromatography. Also the invention describes method of obtaining the claimed composition and assays of the composition content.

EFFECT: high purity grade; stable formulation of atorvastatin and good decomposition and bioavailability rate.

23 cl, 4 tbl, 16 ex

Similar patents RU2332211C2

Title Year Author Number
PHARMACEUTICAL FORMULATION OF ATORVASTATIN 2004
  • Uoterman Kennet Krejg
  • Luner Pol Ehvan
RU2325903C2
PHARMACEUTICAL COMPOSITIONS COMPRISING ATORVASTATIN PREPARED WITHOUT GRANULATION 2004
  • Berkielli Al'Fred
  • Uoterman Kennet Krejg
  • Doehriti Patrik Dehvid
RU2314804C2
COMPOSITE FORMULATION FOR ORAL ADMINISTRATION COMPRISING EZETIMIBE AND ROSUVASTATIN 2014
  • Cho Jung Hyun
  • Kim Jin Cheul
  • Kim Yong Il
  • Lee Seung Jun
  • Park Jae Hyun
  • Woo Jong Soo
RU2683937C2
STABLE PHARMACEUTICAL PREPARATION CONTAINING AMLODIPINE BENZYLATE AND ATENOLOL 1998
  • Rao K. B. Sankara
  • Rao M. S. Sarvesvara
  • Tagore G. V. R.
  • Ramesh K. Kh.
RU2188636C2
PHARMACEUTICAL COMPOSITIONS COMPRISING INHIBITOR OF HMG-REDUCTASE 2000
  • Krikmor Dzhozef Richard
  • Uigginz Norman Al'Fred
RU2206324C1
DOSAGE FORMS FOR ORAL APPLICATION CONTAINING LICARBAZEPINE ACETATE 2008
  • Vashkunselush Teofilu Kardozu Di
  • Santush Lima Rikardu Zhorzhi Duzh
  • Kampush Koshta Ruj Serdejra Di
RU2546521C2
COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE 2014
  • Kang Kwi Man
  • Park Young Joon
  • Park Jun Hong
  • Lee Ji Eun
  • Yoon Seok Kee
  • Kim Yu Jeong
  • Oh Tack Oon
  • Cho Tae Keun
RU2651460C2
PHARMACEUTICAL COMPOSITIONS COMPRISING 5,8,14-TRIAZATETRACYCLO[10,3,1,0(2,11),0(4,9)HEXADECA-2( 11),3,5,7,9-PENTAENE 2002
  • Am Ehnde Mehri Tanja
  • Roj Majkl Kristofer
  • Smit Skott Uehndell
  • Uoterman Kennet Krehjg
  • Mouzes Sara Kristen
  • Kvan Ehrnest Shing
RU2272629C2
STABLE PHARMACEUTICAL COMPOSITION CONTAINING WATER-SOLUBLE VINFLUNINE SALT 2008
  • Pejjar Bruno
  • Avan Zhan-Lui
  • Bugare Zhoehl'
RU2462248C2
PHARMACEUTICAL COMPOSITION FOR TREATING TYPE 2 DIABETES 2010
  • Juan' Kajkhun
  • Sun' Pjaojan
RU2533560C2

RU 2 332 211 C2

Authors

Uoterman Kennet Krejg

Ferdzhione Majkl Brjus

Dzhonson Barbara Ehlis

Dates

2008-08-27Published

2004-06-01Filed